Efficacy and safety of azathioprine in the treatment of chronic actinic dermatitis

Authors

  • Shahzana Naqqash
  • Faria Asad
  • Sabrina Suhail Pal

Keywords:

Chronic actinic dermatitis, azathioprine

Abstract

Background Chronic actinic dermatitis (CAD) is a rare intractable photosensitive predominantly eczematous eruption sometimes with infiltrated plaques on the exposed areas and has a tendency to progress to erythroderma. Along with sun protection, the use of corticosteroids gives only partial response and is associated with many unwanted effects. There are promising reports of usefulness of azathioprine in the treatment of CAD. Objectives To evaluate the efficacy and safety of azathioprine in the treatment of chronic actinic dermatitis in our patients. Patients and methods The study was conducted in the dermatology department of Mayo Hospital, Lahore over a period of 18 months. Patients of CAD fulfilling the inclusion criteria were put on azathioprine 2-3mg/kg/day. The clinical severity was assessed at 0, 1, 3, 6, 9 and 12 months of azathioprine treatment using modified PASI score. Complete hemogram, hepatic and renal function tests, chest X-ray and urinalysis were carried before putting the patients on azathioprine. Hemograms were repeated at monthly intervals while liver enzymes were monitored at 2, 4 and 8 weeks and then at intervals of 2 months. Renal function tests were repeated at 3-monthly intervals. Results Eighteen patients, all men, were studied. The mean duration of disease was 6.5 years. Of the fifteen patients completing 9 months of treatment, six (40%) showed >90% reduction in PASI score, 7 (46.6%) showed >50% reduction while 1 (1.6%) showed <50% improvement. One (1.6%) patient discontinued the treatment on his own after no improvement of 4 months treatment. Conclusion A definite conclusion could not be derived from this study as the number of patients was limited but the azathioprine can be used as an effective and safe treatment modality in chronic actinic dermatitis. 

References

Hawk JLM, Smith NP, Black MM. The photosensitivity disorders. In: Elder DE, Elenitsas R, Jaworsky C, Johnson B Jr, eds. Lever’s Histopathology of Skin. Philadelphia: Lippincott-Raven, 1997: 305-10.

Norris PG, Morris J, Smith NP et al. Chronic actinic dermatitis: an immunologic and photobiologic study. J Am Acad Dermatol 1989; 21: 966-71.

Lim HW, Morrison WL, Kamide R et al. Chronic actinic dermatitis: an analysis of 51 patients in the United States and Japan. Arch Dermatol 1994; 130: 1284-9.

Dawe RS, Crombie IK, Ferguson J. The natural history of chronic actinic dermatitis. Arch Dermatol 2000; 136: 1215-20.

Uetsu N, Okamoto H, Fuji K et al. Treatment of chronic actinic dermatitis with tacrolimus ointment. J Am Acad Dermatol 2002; 47: 881-4.

Morrison JG, Schulz EJ. Treatment of eczema with cyclophosphamide and azathioprine. Br J Dermatol 1978; 98: 203-7.

Vinod KS, Aditi C, Vikram M. Azathioprine in the treatment of Parthenium dermatitis. Int J Dermatol 1998; 37: 299-302.

August PJ. Azathioprine in the treatment of eczema and actinic reticuloid. Br J Dermatol 1982; 107 (Suppl 22): 23.

Leigh IM, Hawk JLM. Treatment of chronic actinic dermatitis with azathioprine. Br J Dermatol 1984; 110: 691-5.

Murphy GM, Maurice PD, Norris PG et al. Azathioprine in chronic actinic dermatitis: a double-blind controlled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol 1989; 121: 639-46.

Callen JP, Spencer LV, Burruss JB et al. Azathioprine: an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991; 127: 515-22.

Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149: 926-37.

Perkins DL, Carpenter CB, eds. Immunobiology of Transplantation. Philadelphia: WB Saunders; 1996.

Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side-effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131: 193-7.

Kirby B, Fortune DG, Bhushan M et al. The Salford Psoriasis Index: a holistic measure of psoriasis severity. Br J Dermatol 2000; 142: 728-32.

Kirby B, Richards HL, Woo P et al. Physical and psychological measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45: 72-6.

Lear JT, English JSC, Jones P, Smith AG. Retrospective review of the use of azathioprine in severe atopic dermatitis. J Acad Dermatol 1996: 35: 642-3.

Berth-Jones T, Takwale A, Tan E et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002; 147: 324-30.

Downloads

Published

2016-12-21

How to Cite

1.
Naqqash S, Asad F, Pal SS. Efficacy and safety of azathioprine in the treatment of chronic actinic dermatitis. J Pak Assoc Dermatol [Internet]. 2016Dec.21 [cited 2024Nov.8];20(4):222-6. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/381

Issue

Section

Original Articles

Most read articles by the same author(s)

1 2 3 4 5 > >>